{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:49:47Z","timestamp":1791931787843,"version":"4.3.4"},"reference-count":140,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1093017"],"award-info":[{"award-number":["APP1093017"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immunotherapy, particularly immune checkpoint inhibitors, have become widely used in various settings across many different cancer types in recent years. Whilst patients are often treated on the basis of the primary cancer type and clinical stage, recent studies have highlighted disparity in response to immune checkpoint inhibitors at different sites of metastasis, and their impact on overall response and survival. Studies exploring the tumor immune microenvironment at different organ sites have provided insights into the immune-related mechanisms behind organ-specific patterns of response to immunotherapy. In this review, we aimed to highlight the key learnings from clinical studies across various cancers including melanoma, lung cancer, renal cell carcinoma, colorectal cancer, breast cancer and others, assessing the association of site of metastasis and response to immune checkpoint inhibitors. We also summarize the key clinical and pre-clinical findings from studies exploring the immune microenvironment of specific sites of metastasis. Ultimately, further characterization of the tumor immune microenvironment at different metastatic sites, and understanding the biological drivers of these differences, may identify organ-specific mechanisms of resistance, which will lead to more personalized treatment approaches for patients with innate or acquired resistance to immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1030147","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T02:21:27Z","timestamp":1668651687000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["The effect of organ-specific tumor microenvironments on response patterns to immunotherapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Jordan W.","family":"Conway","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorja","family":"Braden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Wilmott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Scolyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Pires da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1038\/s41467-022-30549-4","article-title":"The use of single-cell multi-omics in immuno-oncology","volume":"13","author":"Ma","year":"2022","journal-title":"Nat Commun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.697412","article-title":"Applications of single-cell omics in tumor immunology","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T cell exhaustion in infection and cancer","volume":"36","author":"Pauken","year":"2015","journal-title":"Trends Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00767.x","article-title":"PD-1 signaling in primary T cells","volume":"229","author":"Riley","year":"2009","journal-title":"Immunol Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the pd-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Trans Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1104-5","article-title":"Dual biological effects of the cytokines interleukin-10 and interferon-\u03b3","volume":"60","author":"Wilke","year":"2011","journal-title":"Cancer Immunology Immunother"},{"key":"B13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.19.1.565","article-title":"CTLA-4-Mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy","volume":"19","author":"Chambers","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0910341107","article-title":"Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity","volume":"107","author":"Jain","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.2.303","article-title":"Immunologic self-tolerance maintained by Cd25+Cd4+Regulatory T cells constitutively expressing cytotoxic T lymphocyte\u2013associated antigen 4","volume":"192","author":"Takahashi","year":"2000","journal-title":"J Exp Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(02)00362-X","article-title":"The interaction properties of costimulatory molecules revisited","volume":"17","author":"Collins","year":"2002","journal-title":"Immunity"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/ni0702-611","article-title":"CTLA-4: new insights into its biological function and use in tumor immunotherapy","volume":"3","author":"Egen","year":"2002","journal-title":"Nat Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"New Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08631-2","article-title":"Adjuvant therapy failure patterns in the modern era of melanoma management","volume":"27","author":"Rauwerdink","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"New Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000948","article-title":"Evolving impact of long-term survival results on metastatic melanoma treatment","volume":"8","author":"Michielin","year":"2020","journal-title":"J ImmunoTherapy Cancer."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): Distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01211-7","article-title":"Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma","volume":"27","author":"Rozeman","year":"2021","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01188-3","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the international neoadjuvant melanoma consortium (INMC)","volume":"27","author":"Menzies","year":"2021","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013Small-Cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"New Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non\u2013Small-Cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non\u2013Small-Cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: Protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non\u2013Small-Cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"New Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013Small-Cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"New Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013Small-Cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"New Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013Small-Cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"New Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"8512","DOI":"10.1200\/JCO.2022.40.16_suppl.8512","article-title":"EORTC-1416-LCG\/ETOP 8-15 \u2013 PEARLS\/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use","volume":"40","author":"O'Brien","year":"2022","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"New Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"New Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"New Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"New Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"New Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"v851","DOI":"10.1093\/annonc\/mdz394","article-title":"A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)","volume":"30","author":"Fizazi","year":"2019","journal-title":"Ann Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.3390\/ijms20163934","article-title":"The immune landscape of thyroid cancer in the context of immune checkpoint inhibition","volume":"20","author":"Varricchi","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B50","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.3390\/ijms20184413","article-title":"Immune and inflammatory cells in thyroid cancer microenvironment","volume":"20","author":"Ferrari","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12284","article-title":"Triple-negative breast cancer: is there a treatment on the horizon","volume":"8","author":"Yao","year":"2017","journal-title":"Oncotarget"},{"key":"B52","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41523-022-00386-1","article-title":"Immunotherapy for early triple negative breast cancer: research agenda for the next decade","volume":"8","author":"Tarantino","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in Microsatellite-Instability\u2013high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"New Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1067\/msy.2000.103883","article-title":"Liver metastases from breast cancer: long-term survival after curative resection","volume":"127","author":"Selzner","year":"2000","journal-title":"Surgery"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10644","article-title":"Prognostic effect of liver metastasis in lung cancer patients with distant metastasis","volume":"7","author":"Ren","year":"2016","journal-title":"Oncotarget"},{"key":"B58","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cncr.32522","article-title":"Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti\u2013PD-1 therapy","volume":"126","author":"Pires Da Silva","year":"2020","journal-title":"Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2807","article-title":"Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status","volume":"9","author":"Adachi","year":"2020","journal-title":"Cancer Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1159\/000501275","article-title":"Differential organ-specific tumor response to immune checkpoint inhibitors in hepatocellular carcinoma","volume":"8","author":"Lu","year":"2019","journal-title":"Liver Cancer."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.18416","article-title":"Clinical response to immunotherapy targeting programmed cell death receptor 1\/Programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Network Open"},{"key":"B64","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","article-title":"Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer","volume":"5","author":"Emens","year":"2019","journal-title":"JAMA Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort a of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2016.3","article-title":"Liver immunology and its role in inflammation and homeostasis","volume":"13","author":"Robinson","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2015.97","article-title":"Hepatocytes: a key cell type for innate immunity","volume":"13","author":"Zhou","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.00990","article-title":"The role of sinusoidal endothelial cells in the axis of inflammation and cancer within the liver","volume":"11","author":"Wilkinson","year":"2020","journal-title":"Front Physiol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0020-y","article-title":"Liver sinusoidal endothelial cells \u2014 gatekeepers of hepatic immunity","volume":"15","author":"Shetty","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatology."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.11","article-title":"Liver macrophages in tissue homeostasis and disease","volume":"17","author":"Krenkel","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.3748\/wjg.v11.i33.5095","article-title":"Structural and functional aspects of the liver and liver sinusoidal cells in relation to colon carcinoma metastasis","author":"Vekemans","year":"2005","journal-title":"World J Gastroenterology."},{"key":"B72","doi-asserted-by":"publisher","first-page":"175883592211132","DOI":"10.1177\/17588359221113270","article-title":"Approaches to spatially resolving the tumour immune microenvironment of hepatocellular carcinoma","volume":"14","author":"Marsh-Wakefield","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004884","article-title":"Unveiling the tumor immune microenvrionment of organ-specific melanoma metastatic sites","volume":"10","author":"Conway","year":"2022","journal-title":"J ImmunoTherapy Cancer"},{"key":"B74","article-title":"Regulation of interleukin-8 expression in human melanoma cells by the organ environment","volume":"55","author":"Gutman","year":"1995","journal-title":"Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065599","article-title":"Role of NK cell subsets in organ-specific murine melanoma metastasis","volume":"8","author":"Ballas","year":"2013","journal-title":"PLoS One"},{"key":"B76","doi-asserted-by":"publisher","first-page":"eaba0759","DOI":"10.1126\/sciimmunol.aba0759","article-title":"Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis","volume":"5","author":"Lee","year":"2020","journal-title":"Sci Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2386","article-title":"Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab","volume":"24","author":"Joseph","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01701","article-title":"Clinical models to define response and survival with anti\u2013PD-1 antibodies alone or combined with ipilimumab in metastatic melanoma","volume":"40","author":"Pires Da Silva","year":"2022","journal-title":"J Clin Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: An open-label, dose-escalation, and dose-expansion phase ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J Clin Oncol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1902320","DOI":"10.1183\/13993003.02320-2019","article-title":"Host-microbe cross-talk in the lung microenvironment: implications for understanding and treating chronic lung disease","volume":"56","author":"Gosens","year":"2020","journal-title":"Eur Respir J"},{"key":"B81","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/ijms20010116","article-title":"Lung macrophages: Multifunctional regulator cells for metastatic cells","volume":"20","author":"Mukaida","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B82","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1471-2172-9-48","article-title":"CD11c+ antigen presenting cells from the alveolar space, lung parenchyma and spleen differ in their phenotype and capabilities to activate na\u00efve and antigen-primed T cells","volume":"9","author":"Kugathasan","year":"2008","journal-title":"BMC Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.03.010","article-title":"Lung adenocarcinoma and squamous cell carcinoma gene expression subtypes demonstrate significant differences in tumor immune landscape","volume":"12","author":"Faruki","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt205","article-title":"Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)","volume":"24","author":"Dearden","year":"2013","journal-title":"Ann Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.750046","article-title":"Profiling tumor immune microenvironment of non-small cell lung cancer using multiplex immunofluorescence","volume":"12","author":"Peng","year":"2021","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000491","article-title":"Lung metastases share common immune features regardless of primary tumor origin","volume":"8","author":"Garc\u00eda-Mulero","year":"2020","journal-title":"J ImmunoTherapy Cancer."},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3847","article-title":"Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: Influence of tumor origin","volume":"19","author":"Remark","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.4103\/2152-7806.111296","article-title":"Epidemiology and prognosis of brain metastases","volume":"4","author":"Stelzer","year":"2013","journal-title":"Surg Neurol Int"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz246","article-title":"Exclusion of patients with brain metastases from cancer clinical trials","volume":"22","author":"Patel","year":"2020","journal-title":"Neuro-Oncology"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00141-2","article-title":"Evolving treatment options for melanoma brain metastases","volume":"16","author":"Ajithkumar","year":"2015","journal-title":"Lancet Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00545-3","article-title":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","volume":"22","author":"Tawbi","year":"2021","journal-title":"Lancet Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.742971","article-title":"Radiation plus anti-PD-1 therapy for NSCLC brain metastases: A retrospective study","volume":"11","author":"Liao","year":"2021","journal-title":"Front Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14913","article-title":"Site-specific response to nivolumab in renal cell carcinoma","volume":"41","author":"Negishi","year":"2021","journal-title":"Anticancer Res"},{"key":"B97","doi-asserted-by":"publisher","first-page":"a020412","DOI":"10.1101\/cshperspect.a020412","article-title":"The blood\u2013brain barrier","volume":"7","author":"Daneman","year":"2015","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/jcbfm.2012.153","article-title":"Immunologic privilege in the central nervous system and the blood\u2013brain barrier","volume":"33","author":"Muldoon","year":"2013","journal-title":"J Cereb Blood Flow Metab"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01114","article-title":"Astrocytes: Role and functions in brain pathologies","volume":"10","author":"Siracusa","year":"2019","journal-title":"Front Pharmacol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01941","article-title":"Immune microenvironment of brain metastases\u2013are microglia and other brain macrophages little helpers","volume":"10","author":"You","year":"2019","journal-title":"Front Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3390\/cancers4010218","article-title":"Tumor microenvironment in the brain","volume":"4","author":"Lorger","year":"2012","journal-title":"Cancers"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.009","article-title":"The microenvironmental landscape of brain tumors","volume":"31","author":"Quail","year":"2017","journal-title":"Cancer Cell"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3003","article-title":"Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target","volume":"20","author":"Chen","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1985","article-title":"Integrated molecular and clinical analysis of AKT activation in metastatic melanoma","volume":"15","author":"Davies","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3073","article-title":"Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites","volume":"21","author":"Kluger","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.bbrc.2018.03.053","article-title":"Programmed death ligand 1 expression and CD8+ tumor-infiltrating lymphocyte density differences between paired primary and brain metastatic lesions in non-small cell lung cancer","volume":"498","author":"Zhou J","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/annonc\/mdw289","article-title":"Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer","volume":"27","author":"Mansfield","year":"2016","journal-title":"Ann Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02840-0","article-title":"Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscape","volume":"70","author":"Song","year":"2021","journal-title":"Cancer Immunology Immunother"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz207","article-title":"Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer","volume":"30","author":"Kudo","year":"2019","journal-title":"Ann Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"New Engl J Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000466","article-title":"Skeletal muscle and solitary bone metastases from malignant melanoma: multimodality imaging and oncological outcome","volume":"28","author":"G\u00f3mez-Le\u00f3n","year":"2018","journal-title":"Melanoma Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2012.12.004","article-title":"Incidence and consequences of bone metastases in lung cancer patients","volume":"2","author":"Kuchuk","year":"2013","journal-title":"J Bone Oncol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","article-title":"Metastatic sites and survival in lung cancer","volume":"86","author":"Riihim\u00e4ki","year":"2014","journal-title":"Lung Cancer."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non\u2013small cell lung cancer treated with nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.02.010","article-title":"CheckMate 025 randomized phase 3 study: Outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma","volume":"72","author":"Escudier","year":"2017","journal-title":"Eur Urology."},{"key":"B116","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s40425-019-0793-8","article-title":"Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer","volume":"7","author":"Landi","year":"2019","journal-title":"J ImmunoTherapy Cancer"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13597","article-title":"Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"11","author":"Li","year":"2020","journal-title":"Thorac Cancer."},{"key":"B118","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4248\/BR201301003","article-title":"Osteoclasts: New insights","volume":"1","author":"Xu","year":"2013","journal-title":"Bone Res"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2016.03.007","article-title":"The role of osteoblasts in bone metastasis","volume":"5","author":"Ottewell","year":"2016","journal-title":"J Bone Oncol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s44164-022-00008-x","article-title":"Osteosarcoma tumor microenvironment: the key for the successful development of biologically relevant 3D in vitro models","volume":"1","author":"Rodrigues","year":"2022","journal-title":"In Vitro models."},{"key":"B121","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3390\/cells9040976","article-title":"The osteosarcoma microenvironment: A complex but targetable ecosystem","volume":"9","author":"Corre","year":"2020","journal-title":"Cells"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.886305","article-title":"The osteoclast traces the route to bone tumors and metastases","volume":"10","author":"Russo","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-255026","article-title":"Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells","volume":"116","author":"Li","year":"2010","journal-title":"Blood"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.cell.2019.10.029","article-title":"Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy","volume":"179","author":"Jiao","year":"2019","journal-title":"Cell"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.11.002","article-title":"VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging \u03b14\u03b21-positive osteoclast progenitors","volume":"20","author":"Lu","year":"2011","journal-title":"Cancer Cell"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1002\/path.4180","article-title":"Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases","volume":"230","author":"Akfirat","year":"2013","journal-title":"J Pathology."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/s42003-021-02564-6","article-title":"The multiple mechanisms of MCL1 in the regulation of cell fate","volume":"4","author":"Widden","year":"2021","journal-title":"Commun Biol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12935-016-0326-1","article-title":"Survivin: a unique target for tumor therapy","volume":"16","author":"Garg","year":"2016","journal-title":"Cancer Cell Int"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1172\/JCI133334","article-title":"PD-1 blockade inhibits osteoclast formation and murine bone cancer pain","volume":"130","author":"Wang","year":"2020","journal-title":"J Clin Invest"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2021.1936361","article-title":"Frequency of metastasis to the gastrointestinal tract determined by endoscopy in a community-based gastroenterology practice","volume":"34","author":"Kaila","year":"2021","journal-title":"Baylor Univ Med Center Proc"},{"key":"B131","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40792-019-0611-z","article-title":"Long-term survival after adrenal metastasectomy from colorectal cancer: a report of two cases","volume":"5","author":"Tsujimoto","year":"2019","journal-title":"Surg Case Rep"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.816506","article-title":"The lymph node microenvironment may invigorate cancer cells with enhanced metastatic capacities","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1697","article-title":"Clinical landscape of cancer metastases","volume":"7","author":"Riihim\u00e4ki","year":"2018","journal-title":"Cancer Med"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2239-4","article-title":"Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)","volume":"67","author":"Schmid","year":"2018","journal-title":"Cancer Immunology Immunother"},{"key":"B135","doi-asserted-by":"publisher","first-page":"jnccn20283","DOI":"10.6004\/jnccn.2020.7800","article-title":"Melanoma metastases to the adrenal gland are highly resistant to immune checkpoint inhibitors","volume":"4","author":"Borgers","year":"2021","journal-title":"J Natl Compr Cancer Network"},{"key":"B136","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12916-022-02315-2","article-title":"Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice","volume":"20","author":"Ma","year":"2022","journal-title":"BMC Med"},{"key":"B137","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1038\/s41598-021-84568-0","article-title":"Reduced expression of innate immunity-related genes in lymph node metastases of luminal breast cancer patients","volume":"11","author":"Popeda","year":"2021","journal-title":"Sci Rep"},{"key":"B138","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.lungcan.2015.01.016","article-title":"Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers","volume":"88","author":"Kim MY","year":"2015","journal-title":"Lung cancer."},{"key":"B139","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/gutjnl-2018-318070","article-title":"Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response","volume":"69","author":"Wang","year":"2020","journal-title":"Gut"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2010.n.024","article-title":"Expression of chemokine receptor CCR6 as a molecular determinant of adrenal metastatic relapse in patients with primary lung cancer","volume":"11","author":"Raynaud","year":"2010","journal-title":"Clin Lung Cancer."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1030147\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T02:21:30Z","timestamp":1668651690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1030147\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":140,"alternative-id":["10.3389\/fimmu.2022.1030147"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1030147","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]},"article-number":"1030147"}}